[
  {
    "question": "27-year-old pregnant lady living in dairy product farm, presented with fever, neck stiffness. How to treat?",
    "option_a": "ceftriaxone & vancomycin",
    "option_b": "trimethoprim-sulpha , vancomycin & ?",
    "option_c": "ampicillin, ceftriaxone & vancomycin",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Neuro-infectious",
    "explanation": "In pregnant patients, the risk of Listeria monocytogenes is significantly increased, especially with exposures such as dairy farms where unpasteurized milk products might be consumed. Empirical therapy for meningitis in this setting requires coverage for Listeria as well as the common causes of community-acquired meningitis. Listeria enters the host through ingestion of contaminated dairy products. In pregnancy, the altered immune response increases susceptibility. Listeria can cross the placenta, causing severe complications for both the mother and the fetus. The use of ampicillin is essential as it is the drug of choice to treat Listeria infections. A 27-year-old pregnant woman with fever and neck stiffness, particularly with a history of exposure on a dairy farm, raises a high clinical suspicion for Listeria meningitis. This necessitates a regimen that covers both Listeria (ampicillin) and other typical bacterial causes (vancomycin and ceftriaxone). A lumbar puncture with CSF analysis remains the cornerstone for diagnosing meningitis. Blood cultures are also obtained. Differential diagnoses include viral meningitis, other zoonotic infections (such as brucellosis), and tubercular meningitis. The epidemiological context provides important clues for Listeria. The first-line treatment in this context is a combination of ampicillin (for Listeria coverage) along with ceftriaxone and vancomycin (to cover other common pathogens like S. pneumoniae). Ampicillin is considered very safe in pregnancy, and the recommended regimen targets all likely organisms. Pregnancy and lactation considerations are critical: ampicillin is Category B and is preferred over drugs like trimethoprim-sulfamethoxazole, which are contraindicated in pregnancy. Option A (ceftriaxone & vancomycin) lacks Listeria coverage, a key omission given the patient\u2019s environmental exposure and pregnancy. Option B (trimethoprim-sulpha, vancomycin & ?) is problematic because trimethoprim-sulfamethoxazole is contraindicated in pregnancy due to the risk of neural tube defects and kernicterus. Option C (ampicillin, ceftriaxone & vancomycin) appropriately covers the spectrum of pathogens expected in this patient, making it the best choice. Option D is blank. 1. Always include ampicillin in the regimen for pregnant patients with meningitis when there is risk or evidence of Listeria exposure. 2. Exposure to dairy farms or unpasteurized products is a significant risk factor for Listeria. 3. Trimethoprim-sulfamethoxazole should be avoided in pregnancy. Recent research and guidelines (including those from the IDSA and obstetrical societies) reaffirm the need for Listeria coverage in pregnant women with suspected meningitis. Empirical treatment with ampicillin remains the standard of care.",
    "exam_year": "2018",
    "exam_type": "Promotion"
  },
  {
    "question": "patient presented to ER, with meningitis, no papilledema:",
    "option_a": "wait for CT then LP.",
    "option_b": "Give Abx directly",
    "option_c": "Do LP without CT.",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Neuro-infectious",
    "explanation": "The decision to perform a lumbar puncture (LP) without preceding head CT scanning depends on the clinical assessment for increased intracranial pressure. In patients with suspected meningitis who do not have evidence of raised intracranial pressure (e.g., no papilledema, no focal neurologic deficits, and no altered mental status), an immediate LP is indicated. Meningitis can lead to cerebral edema and increased intracranial pressure, which may cause brain herniation if an LP is performed. Papilledema is a clinical sign of raised intracranial pressure. In its absence, the risk of herniation is low, allowing for safe LP performance. This patient, who presents with symptoms of meningitis but lacks papilledema, is evaluated as being at low risk for complications related to LP. Timely CSF sampling is essential for rapid diagnosis and initiation of appropriate therapy. The gold standard for diagnosing meningitis is CSF analysis obtained via LP. In patients with signs of increased intracranial pressure (such as papilledema, focal deficits, or severe altered mental status), a CT scan is warranted prior to LP to avoid the risk of herniation. Differential diagnoses such as encephalitis or intracranial hemorrhage are typically ruled out based on clinical findings and imaging when needed. In the absence of signs of raised intracranial pressure (e.g., papilledema), guidelines recommend performing an LP promptly without waiting for a CT scan. This facilitates rapid diagnosis and timely initiation of antibiotics. However, if there is any concern for increased ICP, obtaining imaging prior to LP is mandatory. This approach applies universally, including in pregnant patients, where delays in diagnosis can adversely affect both mother and fetus. Option A (wait for CT then LP) unnecessarily delays diagnosis in the absence of contraindications, which can worsen outcomes. Option B (give antibiotics directly) may be considered if LP is delayed, but ideally, an LP should be performed promptly to obtain diagnostic CSF before antibiotic administration. Option C (do LP without CT) is the most appropriate based on the patient\u2019s clinical findings. Option D is blank. 1. Always assess for signs of raised intracranial pressure (like papilledema) before LP. 2. In the absence of such signs, do not delay the LP with imaging studies, as prompt diagnosis is essential. 3. If a delay in LP is unavoidable, administer antibiotics immediately. Current guidelines from the IDSA and other neurological associations stress the importance of not delaying LP when contraindications (such as papilledema) are absent. Early CSF analysis is associated with improved outcomes in bacterial meningitis.",
    "exam_year": "2019",
    "exam_type": "Promotion"
  },
  {
    "question": "patient presented with meningitis, what to give:",
    "option_a": "Salmedrole",
    "option_b": "Methylprednisolone",
    "option_c": "Dexamethasone",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Neuro-infectious",
    "explanation": "Adjunctive corticosteroid therapy in bacterial meningitis is used to decrease the inflammatory response triggered by bacterial lysis, which can contribute to neurologic complications. Dexamethasone is the most widely studied steroid in this context. Bacterial cell wall components released during antibiotic-induced lysis can trigger an intense inflammatory response in the subarachnoid space. Dexamethasone, a potent corticosteroid, mitigates this inflammatory cascade, reducing the risk of complications such as hearing loss and neurologic deficits. In patients with bacterial meningitis, particularly those with S. pneumoniae infection, early administration of dexamethasone (ideally before or with the first dose of antibiotics) is associated with improved outcomes. It is critical to administer the steroid promptly to gain its full benefit. While the diagnosis of meningitis is confirmed with CSF analysis via LP, adjunctive therapy with dexamethasone is initiated based on clinical suspicion of bacterial meningitis. Differential treatment considerations include using other steroids or no steroid at all; however, studies have consistently shown the benefit of dexamethasone as adjunct therapy. The current guidelines recommend administering dexamethasone (typically 10 mg IV every 6 hours for 4 days) prior to or concurrently with the first dose of antibiotics in patients with suspected pneumococcal meningitis. For pregnant and lactating patients, while steroid use should always be carefully considered, short-term use of dexamethasone when indicated is generally acceptable given its benefits in reducing neurological complications. Option A (Salmedrole) is not a recognized treatment modality in the management of meningitis. Option B (Methylprednisolone) is a corticosteroid but is not the steroid of choice in bacterial meningitis adjunctive therapy according to current guidelines. Option C (Dexamethasone) is the evidence-based recommendation for adjunctive therapy in bacterial meningitis, making it the correct answer. 1. Dexamethasone should be administered before or with the first dose of antibiotics in suspected bacterial meningitis. 2. Its use has been shown to reduce hearing loss and other neurologic complications in cases of pneumococcal meningitis. 3. Timely administration is critical to obtain the maximum benefit. Recent studies and guidelines (including those from the IDSA) continue to recommend dexamethasone as the adjunctive corticosteroid of choice in bacterial meningitis, especially for pneumococcal infections. Ongoing research is further elucidating the optimal timing and dosing to maximize benefits while minimizing risks.",
    "exam_year": "2019",
    "exam_type": "Promotion"
  },
  {
    "question": "35 years old female has hx of back pain, also she has progressive weakness, with normal brain & spine MRI, he mentioned she came from Africa:",
    "option_a": "Vacuolar myelopathy.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuro-infectious",
    "explanation": "This case describes an HIV\u2010positive patient (suggested by her origin from Africa and clinical context) with a progressive myelopathy. HIV-associated vacuolar myelopathy is a well-known, non-compressive, degenerative spinal cord disorder seen in advanced HIV/AIDS. It typically causes slowly progressive weakness and spasticity in the lower limbs. Vacuolar myelopathy results from the direct and immune-mediated effects of HIV on the spinal cord. Microscopic vacuolation of the myelin in the lateral and posterior columns is pathognomonic. Although cord atrophy may eventually be seen on imaging, early in the disease the MRI may be normal. The process is thought to be related to HIV or its associated cytokines affecting oligodendrocytes and leading to demyelination. Patients usually present with insidious onset of lower extremity weakness, stiffness (spastic paraparesis), impaired vibration and proprioception, and sometimes bladder dysfunction. The normal MRI early on can be misleading, so a high index of suspicion is necessary, particularly in patients with risk factors for HIV infection. The differential diagnoses include subacute combined degeneration due to vitamin B12 deficiency, compressive myelopathies (e.g., tuberculosis of the spine), and other inflammatory myelopathies. Workup involves confirming HIV status, serum B12 levels, CSF analysis and sometimes nerve conduction studies. In many cases, diagnosis is clinical and by exclusion as imaging can be unremarkable early in the disease. There is no specific treatment for vacuolar myelopathy. The primary management is optimization of antiretroviral therapy (ART) to achieve immune reconstitution, which may help slow progression. Supportive measures include physical therapy, spasticity management (e.g., baclofen), and pain control. In pregnant or lactating women, ART regimens recommended by current guidelines (often tenofovir-based, which are considered safe in pregnancy) should be instituted, with careful monitoring of both maternal and fetal status. Option A (Vacuolar myelopathy) correctly describes the condition consistent with the patient\u2019s presentation. The marked answer B is incorrect because it does not correspond to the described pathology. The absence of text for options B, C, and D emphasizes that the intended answer was to recognize vacuolar myelopathy. 1) In an HIV patient, a progressive myelopathy with normal early MRI should raise suspicion for vacuolar myelopathy. 2) Evaluation of vitamin B12 levels is critical as subacute combined degeneration is an important differential. 3) Early initiation or optimization of ART is key in improving overall outcomes. Recent studies underline the importance of early ART initiation to prevent and stabilize neurological complications. While advanced imaging techniques may eventually reveal subtle changes, clinical recognition remains paramount. Updated HIV care guidelines stress aggressive management of HIV to prevent complications like vacuolar myelopathy.",
    "exam_year": "2019",
    "exam_type": "Promotion"
  },
  {
    "question": "what is true about herpes encephalitis:",
    "option_a": "HSV-2 is the most common cause in adults.",
    "option_b": "Fever not significant symptoms.",
    "option_c": "The dose of acyclovir 10mg/kg q12 hours for 14-24 days.",
    "option_d": "Viral load is not associated with severity of the disease.",
    "option_e": "",
    "correct_answer": "D",
    "subspecialty": "Neuro-infectious",
    "explanation": "This case describes an HIV\u2010positive patient (suggested by her origin from Africa and clinical context) with a progressive myelopathy. HIV-associated vacuolar myelopathy is a well-known, non-compressive, degenerative spinal cord disorder seen in advanced HIV/AIDS. It typically causes slowly progressive weakness and spasticity in the lower limbs. Vacuolar myelopathy results from the direct and immune-mediated effects of HIV on the spinal cord. Microscopic vacuolation of the myelin in the lateral and posterior columns is pathognomonic. Although cord atrophy may eventually be seen on imaging, early in the disease the MRI may be normal. The process is thought to be related to HIV or its associated cytokines affecting oligodendrocytes and leading to demyelination. Patients usually present with insidious onset of lower extremity weakness, stiffness (spastic paraparesis), impaired vibration and proprioception, and sometimes bladder dysfunction. The normal MRI early on can be misleading, so a high index of suspicion is necessary, particularly in patients with risk factors for HIV infection. The differential diagnoses include subacute combined degeneration due to vitamin B12 deficiency, compressive myelopathies (e.g., tuberculosis of the spine), and other inflammatory myelopathies. Workup involves confirming HIV status, serum B12 levels, CSF analysis and sometimes nerve conduction studies. In many cases, diagnosis is clinical and by exclusion as imaging can be unremarkable early in the disease. There is no specific treatment for vacuolar myelopathy. The primary management is optimization of antiretroviral therapy (ART) to achieve immune reconstitution, which may help slow progression. Supportive measures include physical therapy, spasticity management (e.g., baclofen), and pain control. In pregnant or lactating women, ART regimens recommended by current guidelines (often tenofovir-based, which are considered safe in pregnancy) should be instituted, with careful monitoring of both maternal and fetal status. Option A (Vacuolar myelopathy) correctly describes the condition consistent with the patient\u2019s presentation. The marked answer B is incorrect because it does not correspond to the described pathology. The absence of text for options B, C, and D emphasizes that the intended answer was to recognize vacuolar myelopathy. 1) In an HIV patient, a progressive myelopathy with normal early MRI should raise suspicion for vacuolar myelopathy. 2) Evaluation of vitamin B12 levels is critical as subacute combined degeneration is an important differential. 3) Early initiation or optimization of ART is key in improving overall outcomes. Recent studies underline the importance of early ART initiation to prevent and stabilize neurological complications. While advanced imaging techniques may eventually reveal subtle changes, clinical recognition remains paramount. Updated HIV care guidelines stress aggressive management of HIV to prevent complications like vacuolar myelopathy.",
    "exam_year": "2019",
    "exam_type": "Promotion"
  },
  {
    "question": "HIV patient with non-enhancing lesion in parietal lobe which is true:",
    "option_a": "prognosis is better if CD4 increase & low viral load.",
    "option_b": "There is treatment for this condition.",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-infectious",
    "explanation": "This case describes an HIV\u2010positive patient (suggested by her origin from Africa and clinical context) with a progressive myelopathy. HIV-associated vacuolar myelopathy is a well-known, non-compressive, degenerative spinal cord disorder seen in advanced HIV/AIDS. It typically causes slowly progressive weakness and spasticity in the lower limbs. Vacuolar myelopathy results from the direct and immune-mediated effects of HIV on the spinal cord. Microscopic vacuolation of the myelin in the lateral and posterior columns is pathognomonic. Although cord atrophy may eventually be seen on imaging, early in the disease the MRI may be normal. The process is thought to be related to HIV or its associated cytokines affecting oligodendrocytes and leading to demyelination. Patients usually present with insidious onset of lower extremity weakness, stiffness (spastic paraparesis), impaired vibration and proprioception, and sometimes bladder dysfunction. The normal MRI early on can be misleading, so a high index of suspicion is necessary, particularly in patients with risk factors for HIV infection. The differential diagnoses include subacute combined degeneration due to vitamin B12 deficiency, compressive myelopathies (e.g., tuberculosis of the spine), and other inflammatory myelopathies. Workup involves confirming HIV status, serum B12 levels, CSF analysis and sometimes nerve conduction studies. In many cases, diagnosis is clinical and by exclusion as imaging can be unremarkable early in the disease. There is no specific treatment for vacuolar myelopathy. The primary management is optimization of antiretroviral therapy (ART) to achieve immune reconstitution, which may help slow progression. Supportive measures include physical therapy, spasticity management (e.g., baclofen), and pain control. In pregnant or lactating women, ART regimens recommended by current guidelines (often tenofovir-based, which are considered safe in pregnancy) should be instituted, with careful monitoring of both maternal and fetal status. Option A (Vacuolar myelopathy) correctly describes the condition consistent with the patient\u2019s presentation. The marked answer B is incorrect because it does not correspond to the described pathology. The absence of text for options B, C, and D emphasizes that the intended answer was to recognize vacuolar myelopathy. 1) In an HIV patient, a progressive myelopathy with normal early MRI should raise suspicion for vacuolar myelopathy. 2) Evaluation of vitamin B12 levels is critical as subacute combined degeneration is an important differential. 3) Early initiation or optimization of ART is key in improving overall outcomes. Recent studies underline the importance of early ART initiation to prevent and stabilize neurological complications. While advanced imaging techniques may eventually reveal subtle changes, clinical recognition remains paramount. Updated HIV care guidelines stress aggressive management of HIV to prevent complications like vacuolar myelopathy.",
    "exam_year": "2019",
    "exam_type": "Promotion"
  },
  {
    "question": "HIV patient with multiple ring enhancement, what is true:",
    "option_a": "starting the antiretroviral improved the cognitive outcome.",
    "option_b": "CMV infection occurred early in the disease.",
    "option_c": "Negative Indian ink exclude the Cryptococcus.",
    "option_d": "Complication of HIV is only related to CD4 count.",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-infectious",
    "explanation": "This case describes an HIV\u2010positive patient (suggested by her origin from Africa and clinical context) with a progressive myelopathy. HIV-associated vacuolar myelopathy is a well-known, non-compressive, degenerative spinal cord disorder seen in advanced HIV/AIDS. It typically causes slowly progressive weakness and spasticity in the lower limbs. Vacuolar myelopathy results from the direct and immune-mediated effects of HIV on the spinal cord. Microscopic vacuolation of the myelin in the lateral and posterior columns is pathognomonic. Although cord atrophy may eventually be seen on imaging, early in the disease the MRI may be normal. The process is thought to be related to HIV or its associated cytokines affecting oligodendrocytes and leading to demyelination. Patients usually present with insidious onset of lower extremity weakness, stiffness (spastic paraparesis), impaired vibration and proprioception, and sometimes bladder dysfunction. The normal MRI early on can be misleading, so a high index of suspicion is necessary, particularly in patients with risk factors for HIV infection. The differential diagnoses include subacute combined degeneration due to vitamin B12 deficiency, compressive myelopathies (e.g., tuberculosis of the spine), and other inflammatory myelopathies. Workup involves confirming HIV status, serum B12 levels, CSF analysis and sometimes nerve conduction studies. In many cases, diagnosis is clinical and by exclusion as imaging can be unremarkable early in the disease. There is no specific treatment for vacuolar myelopathy. The primary management is optimization of antiretroviral therapy (ART) to achieve immune reconstitution, which may help slow progression. Supportive measures include physical therapy, spasticity management (e.g., baclofen), and pain control. In pregnant or lactating women, ART regimens recommended by current guidelines (often tenofovir-based, which are considered safe in pregnancy) should be instituted, with careful monitoring of both maternal and fetal status. Option A (Vacuolar myelopathy) correctly describes the condition consistent with the patient\u2019s presentation. The marked answer B is incorrect because it does not correspond to the described pathology. The absence of text for options B, C, and D emphasizes that the intended answer was to recognize vacuolar myelopathy. 1) In an HIV patient, a progressive myelopathy with normal early MRI should raise suspicion for vacuolar myelopathy. 2) Evaluation of vitamin B12 levels is critical as subacute combined degeneration is an important differential. 3) Early initiation or optimization of ART is key in improving overall outcomes. Recent studies underline the importance of early ART initiation to prevent and stabilize neurological complications. While advanced imaging techniques may eventually reveal subtle changes, clinical recognition remains paramount. Updated HIV care guidelines stress aggressive management of HIV to prevent complications like vacuolar myelopathy.",
    "exam_year": "2019",
    "exam_type": "Promotion"
  },
  {
    "question": "HIV patient has MRI typical for toxoplasmosis",
    "option_a": "Start trimethoprim-sulfamethoxazole",
    "option_b": "Praziquantel",
    "option_c": "doxy",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-infectious",
    "explanation": "In HIV-infected patients, particularly those with CD4 counts below 100 cells/mm\u00b3, cerebral toxoplasmosis is a common opportunistic infection. It typically presents with one or multiple ring-enhancing lesions on MRI, reflecting reactivation of latent Toxoplasma gondii infection in the immunocompromised host. Toxoplasma gondii is an obligate intracellular parasite that, in immunocompetent hosts, is usually contained by an intact immune response. However, in patients with advanced HIV/AIDS, the reduction in cell-mediated immunity (especially low CD4 counts) allows the parasite to reactivate, leading to focal brain abscesses and necrosis, which are visualized as ring-enhancing lesions on neuroimaging. Patients often present with headache, altered mental status, focal neurological deficits, or seizures. The presence of ring-enhancing lesions in an HIV patient should prompt consideration of toxoplasmosis, although the differential includes primary CNS lymphoma and other opportunistic infections. The diagnosis of cerebral toxoplasmosis is primarily clinical and radiographic. MRI findings of one or multiple ring-enhancing lesions, in the appropriate clinical context (advanced HIV, low CD4 count), are highly suggestive. Serological studies (Toxoplasma IgG) support reactivation, and a positive response to empiric anti-toxoplasma therapy further confirms the diagnosis. Differential diagnoses include primary CNS lymphoma, tuberculomas, and other focal brain infections. The gold standard treatment for cerebral toxoplasmosis is a combination of pyrimethamine, sulfadiazine, and folinic acid (leucovorin) to counteract pyrimethamine-induced bone marrow suppression. However, trimethoprim-sulfamethoxazole (TMP-SMX) is also used\u2014both for prophylaxis in patients with CD4 counts <100 cells/mm\u00b3 and, in some protocols or resource-limited settings, as an alternative therapeutic regimen. In the context of pregnancy, pyrimethamine is generally avoided in the first trimester due to teratogenicity, and TMP-SMX is used cautiously near term because of the potential risk for neonatal kernicterus; thus, management in pregnant or lactating patients must be tailored and closely monitored. Among the provided answer choices, Option A (Start trimethoprim-sulfamethoxazole) is the best answer. Although the classical regimen is pyrimethamine with sulfadiazine and folinic acid, TMP-SMX is an acceptable alternative therapeutic agent, particularly given its dual role in prophylaxis and treatment for toxoplasmosis in HIV patients. Option B (Praziquantel) is used for parasitic infections such as schistosomiasis and neurocysticercosis, and Option C (doxycycline) is not indicated for toxoplasmosis. Option D is blank. Early empiric treatment based on characteristic MRI findings can be both diagnostic and therapeutic. TMP-SMX is frequently used for prophylaxis in HIV-positive patients and may serve as an effective alternative treatment regimen when standard therapy is not available or contraindicated. A clinical improvement within 10-14 days following initiation of therapy supports the diagnosis of cerebral toxoplasmosis. Recent studies and updated guidelines acknowledge that while the combination of pyrimethamine, sulfadiazine, and folinic acid remains the standard, TMP-SMX has shown efficacy in treating mild to moderate cerebral toxoplasmosis. This is particularly relevant in resource-limited settings or in patients intolerant to first-line agents. Moreover, its role in prophylaxis has been well established, thereby supporting its use in this scenario.",
    "exam_year": "2021",
    "exam_type": "Promotion"
  },
  {
    "question": "Patient presenting with weight loss and fever, MRI showed frontal epidural collection",
    "option_a": "",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuro-infectious",
    "explanation": "In patients with constitutional symptoms such as weight loss and fever along with a frontal epidural collection on MRI, an infectious etiology must be strongly considered. In many regions and clinical scenarios, tuberculosis is an important differential given its subacute/chronic presentation and ability to produce epidural abscesses via contiguous spread from calvarial osteomyelitis or sinus involvement. Mycobacterium tuberculosis can cause a granulomatous infection that leads to caseation and abscess formation. When TB involves the cranial vault, it may cause calvarial osteomyelitis with secondary epidural abscess formation. The chronic inflammatory process explains the constitutional symptoms such as weight loss and low\u2010grade fever. The presentation of weight loss and fever indicates a subacute to chronic process. A frontal epidural collection on MRI, in this context, is most consistent with an infectious process rather than an acute post-traumatic or post-surgical epidural collection. In endemic areas or in patients with known risk factors, a tubercular etiology is key to consider. Diagnosis requires correlating clinical history with radiologic findings. Contrast-enhanced MRI helps delineate the abscess. Further evaluation with laboratory tests including ESR, CRP, and TB-specific studies (such as interferon-\u03b3 release assays or acid-fast bacilli staining from aspirated material) can help confirm the diagnosis. Differential diagnoses include pyogenic epidural abscess (commonly due to Staphylococcus aureus), fungal abscesses in immunocompromised individuals, and rare noninfectious collections. The management of a tubercular epidural abscess includes prompt initiation of antitubercular therapy (ATT) with an appropriate regimen (typically a four-drug regimen including isoniazid, rifampicin, pyrazinamide, and ethambutol). Surgical drainage is considered if there is significant mass effect or failure of medical therapy. In pregnancy and lactation, first-line antitubercular drugs such as isoniazid, rifampicin, and ethambutol are generally considered safe, though caution is advised with pyrazinamide and contraindications exist for agents like streptomycin due to ototoxicity risks. While the specific options are not provided, the marked Answer B is presumed to represent a tubercular etiology. Given the imaging finding of a frontal epidural collection combined with systemic symptoms, a tubercular abscess is the most likely diagnosis compared to a pyogenic abscess (which typically has an acute, high fever presentation) or noninfectious causes. Therefore, the marked answer B is appropriate. \u2022 Always consider tuberculosis in chronic presentations with constitutional symptoms and focal cranial lesions, especially in endemic areas. \u2022 Distinguishing between tubercular and pyogenic abscesses is essential because the management differs drastically. \u2022 Early diagnosis with appropriate imaging and microbiologic confirmation is key to reducing neurological morbidity. \u2022 In pregnancy, the benefits of ATT usually outweigh the risks; most first-line TB drugs can be safely administered with careful monitoring. Recent reviews and guidelines from the WHO and neurosurgical societies emphasize the importance of early initiation of antitubercular therapy in cases of CNS tuberculosis, including uncommon presentations such as epidural abscesses. There is growing evidence supporting the safety of first-line antitubercular agents during pregnancy when used as indicated, though multidisciplinary management including obstetrics is recommended.",
    "exam_year": "2021",
    "exam_type": "Promotion"
  },
  {
    "question": "Middle age male patient with history of headache, he reported few weeks ago fever, night sweat, weights loss, MRI brain with contrast. He had history of head injury few years ago. Diagnosis?",
    "option_a": "Subdural abscess",
    "option_b": "TB meningitis",
    "option_c": "Sub dural empyema",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuro-infectious",
    "explanation": "Tuberculous (TB) meningitis is a form of chronic meningitis caused by Mycobacterium tuberculosis. It typically presents subacutely with symptoms such as headache, fever, night sweats, and weight loss. Although the patient has a remote history of head injury, the systemic constitutional symptoms point strongly toward a tuberculous process rather than a complication directly related to trauma. TB meningitis occurs when Mycobacterium tuberculosis disseminates hematogenously from a primary focus (often pulmonary) to the meninges. The organism induces a granulomatous inflammatory reaction leading to the formation of a thick, gelatinous exudate predominantly in the basal cisterns. This exudate can cause obstruction of CSF flow, vasculitis, and subsequent infarcts. A middle-aged patient with several weeks of headache, along with fever, weight loss, and night sweats, fits the profile for TB meningitis. The subacute course contrasts with the rapid deterioration seen in acute bacterial infections. The remote history of head injury is less likely to be related since subdural empyema or abscess typically follows more recent trauma or contiguous infections. In TB meningitis, imaging with contrast often reveals basal meningeal enhancement rather than a discrete subdural collection. The key differential diagnoses include TB meningitis, subdural empyema, and subdural abscess. CSF analysis in TB meningitis classically shows a lymphocytic pleocytosis, low glucose, and high protein. MRI with contrast further aids in the diagnosis by demonstrating basal meningeal enhancement. In contrast, subdural empyema typically shows a crescentic or lentiform collection with peripheral enhancement, and patients tend to present with a more fulminant course and focal neurological deficits. The cornerstone of management is early initiation of anti-tubercular therapy: a four-drug regimen (isoniazid, rifampicin, pyrazinamide, and ethambutol) is typically administered, with adjunctive corticosteroids (e.g., dexamethasone) to decrease inflammatory complications. In pregnancy and lactation, most first\u2010line anti\u2010TB drugs (isoniazid, rifampicin, and ethambutol) are considered relatively safe; streptomycin is contraindicated due to its risk of ototoxicity in the fetus. Multidisciplinary management with close maternal and fetal monitoring is advised. Option A (Subdural abscess) and Option C (Subdural empyema) are conditions typically resulting from recent trauma or contiguous spread from sinusitis; they often present acutely with focal neurological deficits and a different imaging profile (collection of pus in the subdural space). The systemic symptoms of night sweats and weight loss strongly favor a diagnosis of TB. Therefore, Option B (TB meningitis) is most consistent with the clinical picture. \u2022 In a patient with a subacute presentation of headache associated with systemic symptoms (fever, weight loss, night sweats), always consider TB meningitis, especially in endemic areas.  \u2022 MRI with contrast is crucial for distinguishing meningeal enhancement of TB meningitis from the extra-axial collections seen in subdural empyema.  \u2022 Past head injury may be an incidental finding unless correlated with a recent history of trauma or infection. Recent guidelines emphasize the early use of anti-tubercular agents along with corticosteroids in managing TB meningitis to lower morbidity and mortality. Advances in diagnostic modalities, including PCR-based detection in CSF and high-resolution imaging, have improved the timeliness and accuracy of diagnosis. Contemporary research also underscores the importance of considering maternal and fetal safety in treatment protocols during pregnancy and lactation.",
    "exam_year": "2022",
    "exam_type": "Promotion"
  },
  {
    "question": "Around 21 YO female pregnant on her 27 weeks lives in dairy farm, presented with history meningitis and shock. CSF: high WBC around 9000, high protein, BG 19. Best empirical Abx:",
    "option_a": "Vanco + Chloramphenicol",
    "option_b": "Vanco+ cefotaxime+ ampicillin",
    "option_c": "Meropenem + Bactrim + Vanco",
    "option_d": "Vanco + ceftriaxone",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuro-infectious",
    "explanation": "Bacterial meningitis in pregnancy mandates a tailored empirical antibiotic regimen to cover the usual pathogens (Streptococcus pneumoniae, Neisseria meningitidis) as well as Listeria monocytogenes\u2014a pathogen of particular concern in pregnant patients. The patient\u2019s history (pregnancy and dairy farm exposure) heightens the risk for Listeria infection. In bacterial meningitis, the invasion of bacteria into the subarachnoid space triggers an intense inflammatory response. This inflammatory cascade damages the blood-brain barrier, leading to an influx of leukocytes (primarily neutrophils), protein leakage, and a reduction in glucose levels in the cerebrospinal fluid. Listeria monocytogenes, a Gram-positive rod, is capable of crossing both the intestinal barrier and the placenta, making it especially dangerous during pregnancy. A 21-year-old pregnant woman presenting with signs of meningitis and shock, along with a CSF profile showing elevated white blood cells (~9000), high protein, and low glucose (19 mg/dL), is highly suggestive of bacterial meningitis. Her residence on a dairy farm further raises the index of suspicion for Listeria exposure. Key differentials include bacterial meningitis (acute presentation with neutrophilic pleocytosis), tuberculous meningitis (which tends to have a subacute course with lymphocytic predominance), and viral or fungal causes (typically with normal glucose and less dramatic CSF protein elevation). CSF Gram stain, culture, and PCR testing are the mainstays for etiologic diagnosis. Empirical therapy in pregnant women with suspected bacterial meningitis should include a regimen that covers S. pneumoniae, N. meningitidis, and Listeria monocytogenes. The combination of vancomycin and a third-generation cephalosporin like cefotaxime or ceftriaxone provides coverage for S. pneumoniae and N. meningitidis, while the addition of ampicillin is essential for covering Listeria. All chosen antibiotics are considered acceptable in pregnancy and lactation, with ampicillin being the drug of choice for Listeria infections. Option A (Vanco + Chloramphenicol) lacks appropriate coverage for both N. meningitidis and Listeria (and chloramphenicol is less favored in pregnancy due to potential fetal toxicity). Option C (Meropenem + Bactrim + Vanco) includes Bactrim (trimethoprim-sulfamethoxazole), which is contraindicated in pregnancy due to potential teratogenicity and the risk of kernicterus in neonates. Option D (Vanco + ceftriaxone) omits ampicillin, thereby failing to cover Listeria. Option B (Vanco + cefotaxime + ampicillin) provides comprehensive coverage for the pathogens in question and aligns with current guidelines. Always ensure Listeria coverage in pregnant patients suspected of meningitis. Exposure history, such as living on a dairy farm, is a critical clue. Early administration of appropriate antibiotics is essential to reduce morbidity and mortality. Contemporary guidelines and clinical studies support the combination of vancomycin, a third-generation cephalosporin (cefotaxime or ceftriaxone), and ampicillin as the standard empirical treatment for suspected bacterial meningitis in pregnant patients. This regimen balances efficacy against common pathogens while ensuring safety for the patient and fetus during both pregnancy and lactation.",
    "exam_year": "2022",
    "exam_type": "Promotion"
  },
  {
    "question": "Same q what to do next",
    "option_a": "Start abx was not the one used in abscess",
    "option_b": "Consult Nsx",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuro-infectious",
    "explanation": "In the management of suspected intracranial infections such as a brain abscess, it is essential to rapidly determine the next step in management. Typically, when imaging suggests an abscess and there is concern for an intracranial collection, the team should mobilize neurosurgical expertise to plan for possible drainage, which is a crucial part of definitive therapy. A brain abscess is a focal, pyogenic infection that evolves through stages\u2014from a cerebritis phase to a capsule-forming phase. The infection may arise from spread from contiguous sites (e.g., otitis media, sinusitis), hematogenous dissemination, or direct inoculation (trauma or neurosurgical procedures). The accumulation of pus and accompanying inflammatory response lead to mass effect and local tissue damage. Patients with a brain abscess may present with headache, focal neurological deficits, seizures, or altered mental status. Constitutional symptoms (fever, malaise) are common, but sometimes signs may be subtle. Radiological study, typically with contrast MRI or CT, is used to identify a rim-enhancing lesion. Consultation with neurosurgery is urgent when imaging confirms an abscess or when the diagnosis is highly suspected. The differential diagnosis includes brain abscess, necrotic tumors, infarcts, or demyelinating lesions. The typical approach is to obtain contrast-enhanced imaging studies. Once a collection is identified, stereotactic aspiration or open drainage not only aids in treatment but also provides material for culture and sensitivity testing to tailor antibiotic therapy. First-line management for a brain abscess involves both initiating appropriate empiric antibiotic therapy (typically covering anaerobes, streptococci, staphylococci, and, depending on the source, gram-negative organisms) and urgent neurosurgical consultation for drainage. The tiered approach is: (1) immediate neurosurgical evaluation and planning for aspiration/drainage, (2) initiation of broad-spectrum IV antibiotics tailored to the likely organisms, and (3) adjustment based on culture results. In pregnancy or lactation, antibiotic choices should be tailored to avoid teratogenic agents while still providing adequate coverage, and surgery proceeds with fetal monitoring as needed. Option A suggests starting antibiotics, but the antibiotic mentioned is not the one recommended for brain abscess management, making it suboptimal. Option B, 'Consult NSx (neurosurgery),' is correct because neurosurgical evaluation is critical for intervention (aspiration or drainage) in a confirmed abscess. Options C and D are not provided. 1. In suspected brain abscess, do not delay neurosurgical consultation even if initiating antibiotics is also important. 2. Drainage not only aids in rapid decompression but also provides culture material to tailor therapy. 3. Imaging with contrast is key to differentiating abscess from other ring\u2010enhancing lesions. Recent guidelines and multiple studies emphasize that early neurosurgical intervention, when appropriate, combined with prompt empiric antimicrobial therapy, is associated with better outcomes. Updated protocols from neurosurgical and infectious disease societies support a team-based approach in these cases.",
    "exam_year": "2023",
    "exam_type": "Promotion"
  },
  {
    "question": "What is first thing to do in case of acute meningitis came to -ER",
    "option_a": "CT",
    "option_b": "Lp if exam no pappiledema",
    "option_c": "Start anti biotics",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Neuro-infectious",
    "explanation": "In acute bacterial meningitis, every minute counts. The core concept is that delays in the initiation of appropriate antibiotics can result in increased morbidity and mortality. Therefore, the immediate administration of empiric antibiotic therapy is paramount. Bacterial meningitis is characterized by the infection of the meninges, leading to an intense inflammatory response in the subarachnoid space. This inflammation can rapidly lead to cerebral edema, increased intracranial pressure, and potential neurologic injury, which is why time-sensitive intervention is critical. Clinically, patients may exhibit fever, neck stiffness (meningismus), altered mental status, and sometimes focal neurological deficits. These signs require high clinical suspicion and prompt management since delaying treatment can worsen outcomes. The differential diagnosis includes viral meningitis, encephalitis, subarachnoid hemorrhage, and other central nervous system infections. The definitive diagnosis relies on cerebrospinal fluid (CSF) analysis from a lumbar puncture (LP); however, if there is any sign of increased intracranial pressure or focal neurological deficits, imaging (CT scan) may precede LP. Nonetheless, if bacterial meningitis is strongly suspected, antibiotics should be administered immediately, preferably after obtaining blood cultures. The tiered management includes: (1) immediate empiric IV antibiotic administration after obtaining blood cultures (and dexamethasone in selected cases such as suspected pneumococcal meningitis), (2) subsequent lumbar puncture for confirmation if safe, and (3) tailoring therapy based on CSF results. In pregnant or lactating patients, antibiotic selection must consider fetal safety; for example, penicillin-based regimens may be preferred when possible. Option A (CT scan) is not required immediately in the absence of focal neurologic deficits or signs of raised intracranial pressure. Option B (LP if no papilledema) can be performed if safe but should not delay antibiotic therapy. Option C ('Start antibiotics') is the correct immediate step to curb the rapidly progressive nature of bacterial meningitis. Option D is not provided. 1. Empiric antibiotic therapy should not be delayed for imaging or lumbar puncture if bacterial meningitis is suspected. 2. Blood cultures should be obtained promptly before antibiotic initiation. 3. Timely administration of antibiotics is associated with improved survival in bacterial meningitis. Current guidelines from the Infectious Diseases Society of America (IDSA) and numerous prospective studies emphasize that rapid initiation of empiric antibiotic therapy in suspected bacterial meningitis is critical, even if imaging or LP must be delayed. This approach has been shown to reduce adverse outcomes significantly.",
    "exam_year": "2023",
    "exam_type": "Promotion"
  },
  {
    "question": "Middle age male patient with history of headache, he reported few weeks ago fever, night sweat, weights loss, MRI brain with contrast. He had history of head injury few years ago.",
    "option_a": "Subdural abscess",
    "option_b": "TB meningitis",
    "option_c": "Sub dural empyema",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Neuro-infectious",
    "explanation": "This question involves differentiating intracranial infectious processes in a middle-aged man presenting with headache and constitutional symptoms (fever, night sweats, weight loss). The distinction between a subdural abscess and a subdural empyema is crucial because the latter represents an unencapsulated purulent collection that is considered a neurosurgical emergency. Subdural empyema is a collection of pus located in the subdural space, typically resulting from the spread of infection from adjacent sites like sinusitis, otitis media, or following head trauma or neurosurgery. In this case, a remote history of head injury might predispose to altered local anatomy, though the constitutional symptoms (fever, night sweats, weight loss) heighten the suspicion for an infectious process. The inflammatory process typically results in a rapid accumulation of purulent material that can compress the underlying brain tissue. Patients with subdural empyema often present with headache, fever, and sometimes focal neurologic deficits or altered mental status as the infection causes increasing intracranial pressure. The subacute course with constitutional symptoms in this scenario favors an infectious etiology over a non-infectious process. Differential diagnoses include tubercular (TB) meningitis\u2014which classically presents with basal meningeal enhancement rather than a subdural collection\u2014and a subdural abscess. On contrast-enhanced MRI, a subdural empyema typically appears as an extra-axial, crescent-shaped, rim-enhancing collection. The distinction is critical because empyema (an unencapsulated collection) is managed differently and is an emergency requiring swift neurosurgical intervention. The standard management for subdural empyema includes urgent neurosurgical drainage (either via burr-hole or craniotomy) combined with broad-spectrum intravenous antibiotics to cover the typical pathogens (including streptococci, staphylococci, and anaerobes). In a pregnant or lactating patient, surgical intervention is still recommended when life-saving; antibiotic regimens must be adjusted to ensure fetal and neonatal safety. Option A, 'Subdural abscess,' uses a term less favored since collections in the subdural space are generally termed \u2018empyemas\u2019 to emphasize their acute, unencapsulated nature. Option B, 'TB meningitis,' is less likely given that TB meningitis typically presents with basal meningeal enhancement and a different clinical picture. Option C, 'Subdural empyema,' accurately reflects the radiographic and clinical scenario presented and is thus the correct answer. 1. Subdural empyema is a neurosurgical emergency\u2014recognize the imaging characteristics and act quickly. 2. Constitutional symptoms such as fever, night sweats, and weight loss in the context of a head lesion should prompt consideration of an infectious etiology. 3. Always differentiate between an abscess (typically parenchymal and encapsulated) and an empyema (extra-axial and unencapsulated). Recent reviews and clinical guidelines underscore the importance of early surgical drainage in subdural empyema, in conjunction with culture-directed antibiotic therapy, to reduce high morbidity and mortality. Updated imaging criteria on MRI further aid in differentiating empyema from other intracranial processes.",
    "exam_year": "2023",
    "exam_type": "Promotion"
  },
  {
    "question": "In HIV on HAART, multiple lesion with ring enhancement. What to give?",
    "option_a": "Praziquental",
    "option_b": "TMP-SMX",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-infectious",
    "explanation": "In HIV-positive patients, especially those on HAART with advanced immunosuppression, the development of multiple ring-enhancing lesions on brain imaging is most commonly associated with reactivation of Toxoplasma gondii, leading to cerebral toxoplasmosis. Cerebral toxoplasmosis results from the reactivation of latent Toxoplasma gondii cysts in patients with low CD4 counts, typically under 100 cells/mm\u00b3. The infection causes focal necrosis and an inflammatory response, which leads to the characteristic ring-enhancing lesions seen on CT or MRI. The immune reconstitution with HAART may modify the clinical course but does not eliminate the risk of reactivation. Patients often present with headache, confusion, focal neurological deficits, or seizures. The multiplicity and ring enhancement of the lesions on brain imaging support the diagnosis of toxoplasmosis over alternatives like primary CNS lymphoma, which more commonly presents with a solitary lesion. The differential diagnosis for ring-enhancing lesions in an HIV patient includes primary CNS lymphoma, tuberculomas, and less commonly brain abscesses or metastases. Empirical anti-toxoplasmosis therapy is often initiated, and improvement on therapy over approximately 10\u201314 days helps confirm the diagnosis. When there is no response, further workup (such as brain biopsy) may be indicated. The first-line treatment for cerebral toxoplasmosis is traditionally a combination of pyrimethamine plus sulfadiazine with leucovorin (folinic acid) to reduce hematologic toxicity. However, high-dose TMP-SMX (trimethoprim-sulfamethoxazole) is recognized as an acceptable alternative, particularly in resource\u2010limited settings or when the classic regimen is not tolerated. In pregnancy, pyrimethamine is generally avoided in the first trimester because of its teratogenic potential. TMP-SMX carries risks as well, so management in pregnant or lactating women must weigh benefits versus fetal risks, often necessitating consultation with infectious disease and maternal\u2013fetal medicine specialists. Option A (Praziquantel) is indicated for neurocysticercosis, not toxoplasmosis. Option B (TMP-SMX) is correct in this context as it represents an acceptable, evidence-based treatment alternative for cerebral toxoplasmosis in HIV patients. Options C and D are not provided. Although the classic therapy is pyrimethamine + sulfadiazine, the options available favor TMP-SMX as the best answer given. 1. In HIV-positive patients, multiple ring-enhancing brain lesions are most commonly due to toxoplasmosis. 2. Empirical anti-toxoplasmosis therapy is both diagnostic and therapeutic\u2014a clinical improvement confirms the diagnosis. 3. Always differentiate toxoplasmosis from primary CNS lymphoma, as management differs significantly. Recent studies have validated high-dose TMP-SMX as an effective alternative regimen for cerebral toxoplasmosis in HIV patients, particularly when the standard pyrimethamine-sulfadiazine regimen is contraindicated or not feasible. Current guidelines also emphasize the importance of rapid initiation of therapy to improve neurologic outcomes.",
    "exam_year": "2023",
    "exam_type": "Promotion"
  },
  {
    "question": "26 Young lady with SLE complained of seizures and confusion this time. SLE nephritis on dialysis. What is your diagnosis? Has CSF high cells with high grade fever MRI of Temporal lobe high signals",
    "option_a": "HSV encephlitis",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-infectious",
    "explanation": "HSV encephalitis is a serious, life\u2010threatening infection of the brain characterized by fever, altered mental status, and seizures. In a patient with SLE, who is often immunocompromised due to both the disease and its treatment, an infection such as HSV becomes a significant concern. The typical MRI finding of high signal intensity in the temporal lobe further supports the diagnosis of HSV encephalitis. HSV, predominantly type 1, is a neurotropic virus that can invade the central nervous system. The virus typically gains access to the brain via the olfactory pathway or through hematogenous spread, leading to an intense inflammatory response. This results in necrosis and edema, particularly in the temporal lobes. In immunocompromised patients, such as those with SLE on dialysis, the risk and severity of HSV reactivation or infection are heightened. The patient\u2019s presentation with new-onset seizures, confusion, and high-grade fever is characteristic of an acute encephalitic process. The CSF findings of increased cell count (pleocytosis) and the MRI showing high signal intensity in the temporal lobe are highly consistent with HSV encephalitis. While SLE can have neuropsychiatric manifestations (neuropsychiatric lupus), the imaging and inflammatory markers strongly point towards an infectious etiology rather than a lupus flare. Diagnosis is typically confirmed with a lumbar puncture showing lymphocytic pleocytosis, elevated protein, and normal to slightly low glucose levels. The gold standard for confirming HSV encephalitis is PCR detection of HSV DNA in the CSF. Differential diagnoses include neuropsychiatric lupus, other viral encephalitides (e.g., varicella zoster, CMV), autoimmune encephalitis, and bacterial meningoencephalitis. Differentiating factors include the pattern of MRI findings (temporal lobe predominance in HSV), specific CSF profiles, and, when needed, serologic or PCR testing. The cornerstone of management is immediate initiation of intravenous acyclovir, which is critical to reduce mortality and neurological complications. First-line treatment with IV acyclovir should be started as soon as HSV encephalitis is suspected, even before confirmatory PCR results are available. Second-line measures include supportive care and, in cases with significant cerebral edema, adjunctive corticosteroid therapy may be considered. In pregnant and lactating women, acyclovir is considered safe and is the recommended therapy due to its benefits outweighing potential risks. Option A (HSV encephalitis) is correct because the patient\u2019s clinical presentation (seizures, confusion, high-grade fever), along with CSF pleocytosis and characteristic temporal lobe MRI findings, is pathognomonic for HSV encephalitis. The absence of other options does not detract from the clarity of the classic findings that confirm HSV encephalitis over other differential diagnoses like neuropsychiatric lupus or bacterial meningitis. 1. Temporal lobe involvement on MRI is a hallmark of HSV encephalitis. 2. Early initiation of IV acyclovir significantly improves outcomes in HSV encephalitis. 3. In immunocompromised patients, such as those with SLE, always maintain a high index of suspicion for infectious etiologies when neurological symptoms develop. Recent clinical guidelines and studies emphasize immediate treatment with acyclovir in suspected HSV encephalitis due to its proven efficacy in reducing mortality and neurological deficits. PCR testing of the CSF remains the gold standard for diagnosis, and ongoing research continues to support the safety of acyclovir during pregnancy and lactation, reinforcing its use in these populations.",
    "exam_year": "2023",
    "exam_type": "Promotion"
  },
  {
    "question": "Young female presented with decrease right eye vision was found to have optic neuritis. Brain MRI showed multiple supratentorial T2 lesions, no previous history of any neurological symptoms what will you do next:",
    "option_a": "Start fingolimod",
    "option_b": "Start beta interferon",
    "option_c": "Observation while doing more confirmatory test",
    "option_d": "Reassure her",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuroimmunology",
    "explanation": "This case describes a young woman presenting with optic neuritis, a common clinically isolated syndrome (CIS) that may be the first manifestation of multiple sclerosis (MS). The presence of multiple supratentorial T2 lesions on her brain MRI suggests dissemination in space, which raises the risk for conversion to clinically definite MS. Early initiation of disease\u2010modifying therapy (DMT) is often recommended in such high\u2010risk individuals. MS is an autoimmune disorder with T-cell\u2013mediated inflammation leading to demyelination and axonal injury in the central nervous system. In optic neuritis, inflammation damages the optic nerve, resulting in the decreased vision witnessed in this patient. The T2 hyperintense lesions represent areas of increased water content due to inflammation and demyelination. Patients with optic neuritis typically present with unilateral vision loss, often accompanied by eye pain on movement. When imaging reveals multiple lesions in the brain, it supports the concept of dissemination in space. When combined with the clinical presentation, it strongly suggests an underlying demyelinating process like MS. The diagnostic workup includes a detailed clinical history, brain (and sometimes spinal) MRI, and often additional tests such as CSF analysis (for oligoclonal bands) and visual evoked potentials. Differential diagnoses include neuromyelitis optica spectrum disorder (NMOSD) and acute disseminated encephalomyelitis (ADEM), which are differentiated by their clinical context and specific ancillary findings. Recent guidelines advocate for early initiation of DMT in patients at high risk for conversion to MS. Beta interferon is one of the first-line options in the treatment of CIS with high lesion burden. For women who are pregnant or lactating, the decision must balance the risks and benefits\u2014with current evidence suggesting that interferon-beta can be considered in pregnancy if needed, though many clinicians may opt to postpone treatment until after pregnancy if the risk is deemed low. Option A (Start fingolimod) is usually reserved as a second-line or escalation therapy due to its side effect profile. Option B (Start beta interferon) is the appropriate first-line DMT, particularly in high-risk CIS. Option C (Observation while doing more confirmatory tests) may delay beneficial treatment in a patient with a high risk of conversion, and Option D (Reassure her) is not acceptable because it ignores the risk of future relapses. 1. Early treatment in high-risk CIS (with multiple MRI lesions) can delay the progression to clinically definite MS. 2. Optic neuritis in the setting of additional T2 lesions should raise strong suspicion for MS. 3. The McDonald criteria allow for diagnosis of MS with a single clinical event plus supportive paraclinical evidence. Recent clinical trials, such as the CHAMPS and BENEFIT studies, have shown that early initiation of DMT, including beta interferon, reduces relapse rates and delays the conversion to definitive MS. Updated guidelines continue to support early treatment in high-risk patients.",
    "exam_year": "2018",
    "exam_type": "Part I",
    "image_url": "page_13.png"
  },
  {
    "question": "MS patient on natalizumab. on the 3rd dose patient started to have shortness of breath, tachycardia and tachypnea. What you will do next?",
    "option_a": "Stop the dose and start prophylaxis management",
    "option_b": "Continue the medication",
    "option_c": "Give half the dose next time",
    "option_d": "Send her for desensitization",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "This MCQ addresses an infusion-related reaction in a patient with MS receiving natalizumab, a monoclonal antibody used as a disease-modifying therapy. Recognizing and managing infusion reactions is vital in the care of patients on biological agents. Natalizumab works by inhibiting leukocyte migration across the blood-brain barrier, thereby reducing inflammation in MS. However, it can induce hypersensitivity or cytokine release reactions during infusion, leading to symptoms such as shortness of breath, tachycardia, and tachypnea. The patient\u2019s symptoms during the infusion\u2014shortness of breath, tachycardia, and rapid breathing\u2014are characteristic of an infusion reaction. Such reactions may be mild to severe and need to be addressed immediately to prevent more severe anaphylactic events. The diagnosis is clinical, based on temporal association with the natalizumab infusion. Differential diagnoses include sepsis, pulmonary embolism, or anxiety-related hyperventilation; however, the timing strongly supports an infusion reaction. The first step in managing a suspected infusion reaction is to stop the infusion immediately. Subsequent management may include supportive care such as oxygen, antihistamines, corticosteroids, or acetaminophen. Pre-medication protocols (prophylaxis) can be instituted for future doses. In pregnant women, the decision to continue natalizumab should carefully weigh risks, with some reports indicating that natalizumab can be used with careful monitoring. Lactating women require similar risk-benefit assessment, with some case reports supporting its cautious use. Option A (Stop the dose and start prophylaxis management) is correct because it both addresses the acute reaction and sets up prevention for future infusions. Option B (Continue the medication) is unsafe given the symptoms. Option C (Give half the dose next time) does not mitigate the risk of an immunologic reaction and is not recommended. Option D (Send her for desensitization) is not standard practice; management typically involves stopping the infusion and implementing prophylactic strategies. 1. Always monitor patients closely during and after the infusion of monoclonal antibodies. 2. Infusion reactions may represent a spectrum from mild to life-threatening and must be managed promptly. 3. Prophylactic measures can help mitigate future reactions. The latest guidelines and post-marketing surveillance data emphasize the importance of monitoring for infusion-related adverse events with natalizumab and recommend immediate cessation of the infusion on symptom onset. Prophylaxis and supportive measures are the accepted standard for managing these reactions.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "Which of the following has an indication in multiple sclerosis disease progression?",
    "option_a": "Cortical atrophy",
    "option_b": "T2 lesions??",
    "option_c": "Gad enhancing lesion",
    "option_d": "T1 lesion",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "This question focuses on identifying neuroimaging markers that indicate disease progression in multiple sclerosis. Cortical atrophy is increasingly recognized as a key marker of neurodegeneration in MS. In MS, chronic inflammation leads to demyelination and eventual neuroaxonal loss. This neurodegeneration results in cortical (gray matter) atrophy, which correlates with irreversible neurological damage and clinical disability. Cortical atrophy is associated with a decline in cognitive and physical functions and is a marker for progression, especially in secondary progressive MS. While T2 lesions, gadolinium-enhancing lesions, and T1 black holes all provide valuable information about disease activity and lesion history, cortical atrophy reflects cumulative tissue loss over time. MRI remains the cornerstone of MS diagnosis and monitoring. Differential imaging markers include: T2 hyperintense lesions (representing active or chronic demyelination), gadolinium-enhancing lesions (indicating active inflammation), T1 hypointense 'black holes' (suggestive of axonal loss), and measures of brain volume or cortical thickness (indicators of atrophy). Each has its specific role in diagnosis and prognosis. While available DMTs primarily target inflammatory processes, monitoring brain atrophy helps guide therapeutic decisions. Early aggressive treatment may slow progression, but in patients with progressive MS, treatment focus may shift towards neuroprotective strategies and symptomatic management. In pregnant or lactating patients, the choice of therapy must account for the safety profiles of medications. Option A (Cortical atrophy) is correct as it has a strong association with long-term disability and neurodegeneration in MS. Option B (T2 lesions) indicate the burden of demyelination but are less specific for progression. Option C (Gad enhancing lesion) signifies active inflammation rather than progression. Option D (T1 lesion) may represent areas of axonal loss but is less sensitive and specific than measures of cortical atrophy for overall progression. 1. Brain atrophy, particularly cortical atrophy, is a robust imaging biomarker for MS progression. 2. While lesion count on T2-weighted images is important for diagnosis, atrophy measurements are more predictive of long-term disability. 3. Advanced MRI techniques are increasingly useful for quantifying neurodegeneration in MS. Recent research supports the use of brain volume metrics, including cortical atrophy, as prognostic indicators in MS. Updated imaging protocols and advanced volumetric analyses are being incorporated into clinical trials and practice to better monitor disease progression.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "A 19-year-old female presented with history of seizures. One month before presentation she had depression, social isolation and personality changes and hallucination she was taken to a psychiatrist and was given antipsychotic medications, exam unremarkable except for orofacial dyskinesia:",
    "option_a": "NMDA encephalitis",
    "option_b": "Tardive dyskinesia",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "This case involves a young female with a history of seizures and a recent onset of psychiatric symptoms (depression, social isolation, personality changes, and hallucinations) who subsequently developed orofacial dyskinesia. This constellation of symptoms is highly characteristic of anti-NMDA receptor encephalitis. NMDA receptor encephalitis is an autoimmune encephalitis in which antibodies target the NMDA receptors in the brain, leading to receptor internalization and subsequent neuronal dysfunction. This results in a wide range of symptoms including psychiatric manifestations, seizures, and movement disorders such as orofacial dyskinesias. Typical clinical presentation of NMDA receptor encephalitis involves a prodromal phase followed by prominent psychiatric symptoms, seizures, and movement abnormalities (often orofacial dyskinesias). Although antipsychotic medications can cause movement disorders (e.g., tardive dyskinesia), the rapid onset and the presence of seizures in this young patient point more convincingly toward NMDA receptor encephalitis. Diagnosis involves a high index of suspicion based on clinical presentation. Confirmation requires CSF analysis for anti-NMDA receptor antibodies, EEG (which may show diffuse slowing or epileptiform activity), and sometimes brain MRI (although it may be normal or nonspecific). Differential diagnoses include: tardive dyskinesia due to antipsychotic use, other autoimmune encephalitides, and primary psychiatric disorders. First-line treatment involves immunotherapy with high-dose corticosteroids, IV immunoglobulin (IVIG), or plasma exchange. If an underlying neoplasm is identified, surgical removal is indicated. In pregnancy, immunotherapy should be balanced against potential fetal risks, though corticosteroids and IVIG are generally considered safe when needed; careful multidisciplinary management is essential. Lactating patients require individual risk-benefit discussions regarding the continuation of immunotherapy. Option A (NMDA encephalitis) is correct because the patient\u2019s sequence of psychiatric symptoms, seizures, and orofacial dyskinesia is classic for this condition. Option B (Tardive dyskinesia) is less likely given the short duration of antipsychotic exposure (typically requiring prolonged use) and its lack of association with seizures. Options C and D are not provided, but based on the clinical scenario, NMDA encephalitis remains the most consistent diagnosis. 1. Anti-NMDA receptor encephalitis classically presents with psychiatric symptoms followed by seizures and abnormal movements such as orofacial dyskinesia. 2. Early recognition and prompt immunotherapy significantly improve the prognosis. 3. Tardive dyskinesia generally requires longer exposure to antipsychotics and does not typically include a seizure component. Recent studies have highlighted the importance of early CSF antibody testing in suspected cases of NMDA receptor encephalitis. Updated management guidelines recommend early immunotherapy, and emerging research supports the safety and efficacy of first-line treatments even in special populations such as pregnant or lactating women when clinically indicated.",
    "exam_year": "2018",
    "exam_type": "Part I"
  }
]